Necrotizing Enterocolitis - Pipeline Insight, 2024

This “Necrotizing Enterocolitis - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Necrotizing Enterocolitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Necrotizing Enterocolitis Understanding

Necrotizing Enterocolitis: Overview

Necrotizing enterocolitis (NEC), which typically occurs in the second to third week of life in premature, formula-fed infants, is characterized by variable damage to the intestinal tract, ranging from mucosal injury to full-thickness necrosis and perforation. In severe cases of NEC, a hole may form in the wall of the intestine. If this occurs, the bacteria normally found inside the intestine can leak into the abdomen and cause widespread infection. This is considered a medical emergency.

Necrotizing Enterocolitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Necrotizing Enterocolitis pipeline landscape is provided which includes the disease overview and Necrotizing Enterocolitis treatment guidelines. The assessment part of the report embraces, in depth Necrotizing Enterocolitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Necrotizing Enterocolitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Necrotizing Enterocolitis R&D. The therapies under development are focused on novel approaches to treat/improve Necrotizing Enterocolitis.

Necrotizing Enterocolitis Emerging Drugs Chapters

This segment of the Necrotizing Enterocolitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Necrotizing Enterocolitis Emerging Drugs

IBP-9414: Infant Bacterial Therapeutics IBP-9414 for the prevention of necrotizing enterocolitis (NEC) contains the active substance Lactobacillus reuteri, which is a co-evolved human bacterial strain naturally present in breast milk. Lactobacillus reuteri is a live bacteria known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. In June 2016, IBT commenced the Safety and Tolerability study. In late 2017, the results demonstrated a similar safety and tolerability profile in the active group as in the placebo group. The pivotal Phase III study, the Connection study, commenced July 4, 2019.

STP-206: Leadiant Biosciences Mechanism of Action is Bacteria replacements. The drug is currently in phase 2 of clinical trials for the treatment of NecrotizingEnterocolitis.

Necrotizing Enterocolitis: Therapeutic Assessment

This segment of the report provides insights about the different Necrotizing Enterocolitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Necrotizing Enterocolitis

There are approx. 4+ key companies which are developing the therapies for Necrotizing Enterocolitis. The companies which have their Necrotizing Enterocolitis drug candidates in the most advanced stage, i.e. phase III include, Infant Bacterial Therapeutics Biopharma.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Necrotizing Enterocolitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Necrotizing Enterocolitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Necrotizing Enterocolitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Necrotizing Enterocolitis drugs.

Necrotizing Enterocolitis Report Insights

• Necrotizing Enterocolitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Necrotizing Enterocolitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Necrotizing Enterocolitis drugs?
• How many Necrotizing Enterocolitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Necrotizing Enterocolitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Necrotizing Enterocolitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Necrotizing Enterocolitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Infant Bacterial Therapeutics
• Leadiant Biosciences
• Noveome

Key Products

• IBP-9414
• STP-206
• ST 266

This product will be delivered within 2 business days.